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Randomised controlled trials on 
convalescent plasma in patients with 
COVID-19 have given conflicting results 
with regards to therapeutic benefit.1,2 
Possible factors include previous 
seroconversion in reci pients1 and late 
treatment when proinflammatory 
factors dominate tissue damage.2 
Patients with impaired immune 
function due to B-cell depletion might 
develop chronic SARS-CoV-2 infections, 
which can be controlled by convalescent 
plasma transfusions.3
Here, we report our experience with 
convalescent plasma administered 
to 14 patients with COVID-19 (seven 
[50%] were female, and median age 
was 65 years [IQR 58–70]) with acquired 
immunodeficiencies due to: solid 
organ transplantation (eight patients), 
allogeneic stem cell transplantation 
(four patients), or active haematological 
malignancy (two patients). All 
patients had no detectable IgG against 
SARS-CoV-2 at the time of transfusion 
(LIAISON SARS-CoV-2 S1/S2 IgG, 
DiaSorin, Stillwater, MN, USA). Mean 
time from positive SARS-CoV-2 PCR 
to transfusion was 5·14 days (SD 5·14). 
Median initial disease severity on the 
10-point WHO Clinical Progression 
Scale was 5 (range 4–6). Convalescent 
plasma preparations were subjected 
to pathogen inactivation (Intercept 
Blood System, Cerus, Concord, CA USA), 
as reported previously.4 All plasma 
preparations had plaque reduction 
neutralisation test 50 (PRNT50) values 
of 40 or higher. 11 patients received 
three transfusions, two received two 
transfusions, and one patient received 
one transfusion, each of 200 mL.
Transfusion of convalescent plasma 
was well tolerated. 13 patients 
developed detectable anti-SARS-CoV-2 
IgG 24–48 h after the last transfusion. 
Eight (57%) of 14 patients showed 
clinical improvement on day 5 after 
the last transfusion, defined as an 
improvement of 1 point or more on 
the WHO Clinical Progression Scale. 
12 (86%) patients were discharged 
from hospital. Two (14%) patients 
died due to a secondary infection. 
Interestingly, we found a significant 
correlation between the serum level 
of anti-SARS-CoV-2 IgG after the last 
transfusion and the degree of clinical 
improvement on day 5 (figure). Because 
an early intrinsic antibody response 
to SARS-CoV-2 infection in severely 
immunocompromised patients seems 
unlikely,5 we assume that the IgG 
titres reflected transfused anti-SARS-
CoV-2 IgG from the convalescent 
plasma. More importantly, our data 
suggest that anti-SARS-CoV-2 IgG 
serum titres of more than 20 IU/mL 
are able to confer a more than 2-point 
improvement in the WHO Clinical 
progression Scale (figure) and could act 
to guide the use of convalescent plasma 
transfusions.
In summary, our pilot study, which 
is limited by the small number of 
participants, suggests patients who 
are immunosuppressed with early 
stage SARS-CoV-2 infection and no 
detectable anti-SARS-CoV-2 IgG 
are potential candidates for treatment 
with convalescent plasma, and 
the IgG titre after transfusion could be 
used as a potential predictive parameter 
for treatment success.
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Figure: Correlation between anti-SARS-CoV-2 IgG titres 24–48 h after the 
last transfusion and improvement in clinical status in patients with 
COVID-19 (n=14)
Datapoints represent each patient. Clinical improvement was defined as an 
improvement of 1 point or more on the 10-point WHO Clinical Progression 
Scale for COVID-19 5 days after the last transfusion and the clinical status before 
transfusion.
































Anti-SARS-CoV-2 IgG after transfusion (IU/mL)
R2 = 0·54
p = 0·003
